Skip to main content
TipRanks
Go Ultimate75% OFF

Dianthus Therapeutics (87E) Stock Price & Analysis

0 Followers

87E Stock Chart & Stats

€78.50€0.00(0.00%)
At close: 5:30 PM GMT+1
€80€90Aug 12Sep 11Sep 24Oct 7Nov 4Nov 9
Day’s Range
EUR 77.50 - EUR 78.50
52-Week Range
EUR 30.60 - EUR 99.50
Previous Close
EUR 78.50
Volume
N/A
Average Volume (3M)
63
Market Cap
EUR 4.36B
Enterprise Value
EUR 4.21B
Total Cash (Recent Filing)
EUR 837.78M
Total Debt (Recent Filing)
EUR 1.21M
Price to Earnings (P/E)
2827.7
Beta
0.13
Next Earnings
Mar 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage

Extremely low leverage limits financial risk from borrowing and preserves flexibility for research, development, and other corporate needs. The sizable equity base gives Dianthus more capacity to fund its clinical-stage strategy without the added pressure of substantial debt service.

Focused Therapeutic Strategy

A focused antibody strategy around Complement Factor C1s provides a clear scientific direction rather than a highly dispersed development portfolio. Targeting severe autoimmune and inflammatory diseases could support meaningful clinical value if development successfully demonstrates efficacy and safety.

Expanded Capital Base

Substantial growth in equity and assets strengthens the company’s financial foundation for a clinical-stage biotechnology model. This larger capital base can support continued development activity and provides more flexibility than a similarly positioned company with a smaller funding cushion.

Bears Say

No Commercial Revenue

Without marketed products, the company lacks a recurring commercial revenue stream to fund operations or validate its business model through customer demand. Financial progress therefore remains dependent on clinical development and future financing or partnering outcomes.

Persistent Cash Burn

Heavy negative operating and free cash flow indicates that ongoing research and corporate activities consume substantial cash. If this burn persists, Dianthus will need continued access to funding, which can constrain strategic flexibility and increase dependence on external capital.

Development-Stage Losses

The company remains far from breakeven because development spending materially exceeds its small and volatile revenue base. Continued net losses leave profitability dependent on successful clinical progress, future commercialization, and the eventual scale-up of operating revenue.

Dianthus Therapeutics News

87E FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was €30.60 and its highest was €99.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is €4.36B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 116 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 04, 2026. The company reported -€0.732 earnings per share for the quarter, beating the consensus estimate of -€0.854 by €0.122.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.87.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 56,312,714 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -€0.732 in its last earnings report, beating expectations of -€0.854. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Hedge funds hold Dianthus Therapeutics shares: the largest hedge-fund position in Dianthus Therapeutics is 780,261,126 shares, and hedge funds decreased their holdings by 3.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology